Immunohistochemical Expression of Ck-19 in Thyroid Nodules and Its Correlation with Histopathology by Suriyaprabha, P
  
“IMMUNOHISTOCHEMICAL EXPRESSION OF CK-19 
IN THYROID NODULES AND ITS CORRELATION 
WITH HISTOPATHOLOGY” 
 
Dissertation submitted in 
Partial fulfillment of the regulations required for the award of 
M.D. DEGREE 
In 
PATHOLOGY – BRANCH III 
 
 
THE   TAMILNADU 
DR. M.G.R. MEDICAL UNIVERSITY 
CHENNAI 
APRIL 2016 
 
  
DECLARATION 
 
          I hereby declare that the dissertation entitled  
“IMMUNOHISTOCHEMICAL EXPRESSION OF CK-19 IN THYROID 
NODULES AND ITS CORRELATION WITH HISTOPATHOLOGY” is a 
bonafide research work done by me in the Department of Pathology, 
Coimbatore Medical College during the period from July 2014 to July 
2015 under the guidance and supervision of Dr. A .Dhanalakshmi M.D., 
Associate Professor Department of Pathology, Coimbatore Medical 
College. 
This dissertation is submitted to The Tamilnadu Dr.MGR Medical 
University, Chennai towards the partial fulfilment of the requirement for 
the award of M.D., Degree (Branch III) in Pathology. I have not 
submitted this dissertation on any previous occasion to any University for 
the award of any Degree. 
 
 
Place: Coimbatore  
Date:                     Dr.P. Suriyaprabha 
 
                                      
  
  
CERTIFICATE 
 
              This is to certify that the dissertation entitled 
“Immunohistochemical expression of CK-19 in thyroid nodules and its 
correlation with histopathology” is a record of bonafide  work done by  
Dr. P. Suriyaprabha in the Department of Pathology, Coimbatore 
Medical College, Coimbatore under the guidance and supervision of  
 Dr. A. Dhanalakshmi M.D., Associate Professor, Department of 
Pathology, Coimbatore Medical College and submitted in partial 
fulfilment of the requirements for the award of M.D. Degree (Branch III) 
in Pathology by The Tamilnadu Dr. MGR Medical University, Chennai.    
 
 
Guide                                         Head of the Department 
 Dr. A. Dhanalakshmi, M.D.,      Dr. C.Lalitha, M.D., 
Associate Professor,                         Professor, 
Department of Pathology,                           Department of Pathology, 
Coimbatore medical college,           Coimbatore medical college, 
Coimbatore.                                       Coimbatore.                       
 
 
 
                                                                                                                                                     
Dr. A.EDWIN JOE.M.D 
The Dean, 
                                              Coimbatore medical college, 
                                              Coimbatore. 
 

 
 
ACKNOWLEDGEMENT 
 
To begin with, I thank the almighty GOD for his blessings and 
guidance in all my activities. 
I wish to express my sincere thanks to the honourable Dean,   
Dr. A.Edwin Joe, M.D., Coimbatore Medical College and Hospital, 
Coimbatore, for permitting me to conduct this  study in this hospital. 
I extend my gratefulness and thanks to Prof  Dr. C. Lalitha, M.D., 
Professor and Head, Department of Pathology for her able guidance and 
support and also for providing  all facilities  to carry out this study.                                                                                                                         
It‟s a great pleasure to express my humble gratitude to my guide 
Dr. A. Dhanalakshmi,  M.D., Associate Professor, Department of  
Pathology for her  innovative suggestions, constant encouragement and 
guidance  during this endurable work. 
I thank Professor  Dr. A. Arjunan, M.D.,  all the Associate 
Professors , all Assistant Professors and Tutors of  Pathology department, 
Coimbatore medical college for their constant support and valuable 
opinions. 
I wish to thank all my colleagues for their timely help and 
encouragement. 
I would like to thank the department of General Surgery and 
department of Surgical Oncology for their constant support. 
I thank all the technical staffs for their kind cooperation. 
 
 
It would not be complete without mention of my husband,  
Dr. S. Arulananthan, B.D.S., for his encouraging words, extensive help 
and constant support throughout this project. 
     I express my gratitude to my lovable child A. Shriram, my dear 
brother  P. Parthiban  Pradeep, B.E., my respectable parents, other family 
members and my friends for their tireless support, encouragement, 
prayers and source of strength all through this endeavour. 
Finally, I am obliged to all the patients without whom this study 
would not have been possible and I dedicate this study to them. 
  
       
         
            
  
  
 
  
 
 
CONTENTS 
                       
 
 
 
 
 
 
SI.NO. PARTICULARS PAGE NO. 
1. INTRODUCTION 1-3 
2. AIM & OBJECTIVES 4 
3. REVIEW OF LITERATURE 5-52 
4. MATERIALS AND METHODS 53-62 
5. OBSERVATION AND RESULTS 63-80 
6. DISCUSSION 81-88 
7. SUMMARY AND CONCLUSION 89-91 
8. BIBLIOGRAPHY  
9. ANNEXURES  
 
ANNEXURE  I – PROFORMA & 
CONSENT FORM 
 
 ANNEXURE II – MASTER CHART  
 ANNEXURE III - ABBREVIATIONS  
 
 
LIST OF TABLES 
 
SI.NO TITLE 
PAGE 
NO 
1 Age distribution of thyroid nodules 64 
2 Sex distribution of thyroid nodules 66 
3 Distribution of different thyroid neoplasms 67 
4 Association of age with histopathological diagnosis 69 
5 Association of sex with histopathological diagnosis 71 
6 Variants of different thyroid carcinomas 73 
7 Incidence of  Papillary Carcinoma variants 75 
8 Intensity of staining of cytokeratin19 in thyroid nodules 76 
9 Intensity of staining of cytokeratin19 in well 
differentiated thyroid carcinoma 
78 
10 Statistical analysis data of  cytokeratin19 staining in 
thyroid nodules 
80 
 
  
 
 
LIST OF CHARTS 
SI.NO TITLE 
PAGE 
NO 
1 Age distribution of thyroid nodules 65 
2 Sex distribution of thyroid nodules 66 
3 Distribution of various thyroid neoplasms 68 
4 Association of age with histopathological diagnosis 70 
5 Association of sex with histopathological diagnosis 72 
6 Proportion of  variants of  different thyroid carcinomas 74 
7 Percentage of  variants of papillary carcinoma 75 
8 Intensity of staining of cytokeratin19 in thyroid nodules 77 
9 Intensity of staining of cytokeratin19 in papillary 
carcinoma of thyroid 
79 
 
  
 
 
LIST OF COLOUR PLATES 
 
S.NO COLOUR PLATES 
1 Papillary carcinoma of thyroid- H& E (10X)  
2 Papillary carcinoma of thyroid showing nuclear grooves and 
nuclear pseudoinclusion – H & E (40X)  
3 Diffuse 3+ cytoplasmic  positivity of cytokeratin19 in papillary 
carcinoma (10X) 
4 2+ positivity of Cytokeratin19 in papillary carcinoma (10X) 
5 Follicular variant of papillary carcinoma – H & E (10X) 
6 Follicular variant of papillary carcinoma showing 2+ positivity 
with cytokeratin19 (10X) 
7 Follicular variant of papillary carcinoma showing 1+ positivity 
with cytokeratin19 (10X) 
8 Follicular carcinoma of thyroid with capsular invasion- H & E 
(10X) 
9 Follicular carcinoma thyroid showing vascular invasion- H & E 
(10X) 
10 Follicular carcinoma of thyroid showing focal 1+ positivity with 
cytokeratin19 (10X) 
11 Follicular carcinoma showing negative staining with 
cytokeratin19 (10X) 
12 Follicular adenoma – H & E (10X) 
13 Follicular adenoma showing focal 1+ positivity with 
cytokeratin19 (10X) 
14 Follicular adenoma showing negative staining with cytokeratin19 
(10X) 
15 Metastatic papillary carcinoma deposits in lymph node – H & E 
(10X) 
16 Diffuse 3+ positivity of cytokeratin19 in metastatic papillary 
carcinoma deposits foci in lymph node (10X) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
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INTRODUCTION 
          Thyroid neoplasms constitute the most commonly occurring 
endocrine tumors worldwide. Thyroid nodules commonly occur between 
30-60 years of age. About 4% to 8% of adult women and 1% to 2% of 
adult men present with thyroid nodules that can be identified by physical 
examination. With the advent of ultrasonography, the detection rate has 
increased to 30%. Majority of the thyroid nodules are benign with 
malignant nodules comprising only 10%. Thyroid tumors can arise either 
from the epithelial cells lining the follicles or from parafollicular C cells. 
             Malignant tumors of thyroid are prevalent worldwide. A survey 
conducted by WHO during 2010 revealed that around 44,670 new cases 
had appeared of which 1690 deaths occurred due to thyroid malignancy. 
Papillary carcinoma is the most common malignant tumor constituting 
80-85% of all the thyroid carcinomas and that too the classic type, 
followed by follicular carcinoma comprising 10- 15%.But the mortality 
rate is only 6.5%. According to the surveillance and epidemiology, the 10 
year survival rates for malignant thyroid tumors are 
 Papillary carcinoma – 98% 
 Follicular carcinoma – 92% 
 Medullary carcinoma – 80% 
 Undifferentiated carcinoma – 13% 
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Early diagnosis of thyroid tumors and appropriate management 
will prolong the survival rate of patients. However  distinguishing various 
thyroid lesions by hematoxylin and eosin sections alone is really 
challenging to pathologist. 
This is well stated by Baloch and Livolsi as, “Thyroid follicular 
lesions are the bane of the Pathologist” in their article. 
As many thyroid tumors have overlapping morphological features, 
exact diagnosis is very essential for surgical and post- operative 
management of patients. Especially papillary carcinoma and its follicular 
variant which mimics follicular carcinoma can be treated by simple 
thyroidectomy, if diagnosed early.  Differentiation of follicular adenoma 
and follicular carcinoma depends on capsular and vascular invasion. 
When it is inconclusive, false diagnosis of benignity may lead to 
extensive vascular dissemination and dismal prognosis. An increasing 
number of  immunohistochemical markers are used in the differential 
diagnosis of both benign and malignant thyroid lesions. They are 
cytokeratin19, CD56, HBME-1, Galectin-3, Ret oncoprotein, p17, 
CITED1, PAX8 and EGFR (epidermal growth factor receptor). 
Cytokeratin19, a low molecular weight protein of 40kDa belonging 
to keratin family is an intermediate filament involved in protein binding 
and organization of myofibers. Cytokeratin19 is extensively used in the 
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diagnosis of thyroid tumors. Many studies have reported it as sensitive 
marker in differentiating benign from malignant thyroid tumors. 
The purpose of this study is to analyse the usefulness of 
Cytokeratin19 in differentiating thyroid nodules by grading the intensity 
of staining in cytoplasm of cells and to correlate it with the 
histopathology. 
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AIM OF THE STUDY 
     To study the immunohistochemical expression of Cytokeratin19 in 
various types of  thyroid  nodules and its correlation with histopathology. 
OBJECTIVES: 
1. To study the expression of Cytokeratin19 in different thyroid 
lesions. 
2. To study the value of cytokeratin19 in  differentiating  benign  
from malignant thyroid nodules. 
3. To study the correlation of   cytokeratin19 expression in thyroid 
nodules with histopathology.  
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REVIEW OF LITERATURE 
Thyroid gland is the major endocrine gland that controls the 
metabolic functions of the human body. THOMAS WHARTON, an 
English physician and anatomist from London, in 1656 named this 
endocrine gland as THYROID GLAND, as it resembled the SHIELD, 
used in Ancient Greece. 
The occurrence of palpable thyroid nodules in adults is about 5%. 
The main goal in clinical medicine is to identify malignant lesions in a 
cost effective manner. In iodine deficient areas thyroid nodules are more 
frequent with higher occurrence in women and also with increasing age. 
The palpability of nodules depends on its location in the thyroid gland 
and anatomy of patient’s neck. These nodules can be detected by thyroid 
ultrasound, CT scan and pathological studies. Nowadays, image guided 
biopsies or FNAC is more helpful. But FNAC is not confirmatory test as 
follicular adenoma and follicular carcinoma cannot be differentiated by 
this test. 
Papillary carcinoma which is identified by its characteristic nuclear 
features  like  nuclear grooves , intranuclear cytoplasmic inclusions  are 
also present in atypical adenoma ,Hyalinising trabecular adenoma, 
medullary carcinoma , parathyroid adenoma  and  paraganglioma. 
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Hence, histopathological study of  the tissue sections are essential. 
But certain tumors of thyroid have overlapping features and often 
pose a diagnostic difficulty especially in the tumors having follicular 
pattern such as follicular adenoma, follicular carcinoma and follicular 
variant of papillary carcinoma. 
As the prognosis and management are different, differentiating 
these lesions is essential. As follicular patterned lesions are identified 
based on cytological criteria like nuclear grooving, nuclear overlapping 
and intranuclear pseudoinclusions , interobserver variations are common. 
This leads to inappropriate nomenclature or diagnosis. 
Thyroid follicular lesions are either capsulated or   unencapsulated 
but with follicular architecture. The four important lesions that should be 
differentiated are 
 Hyperplastic colloid nodule 
 Follicular adenoma 
 Follicular carcinoma 
 Follicular  variant  of  papillary  carcinoma 
 
In an attempt to overcome this diagnostic difficulty many 
immunohistochemical markers are evaluated in distinguishing papillary 
thyroid carcinoma from other follicular patterned lesions.  They are 
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CK19, HBME-1, galectin-3, CD 56, Leu-7 (CD 57), CITED-1, 
fibronectin-1, CD 15, PAX8, CD 44 and platelet derived growth factor. 
CD 56 expression is lost in papillary carcinoma but is expressed in benign 
and other malignant lesions of thyroid including normal thyroid. 
EMBRYOLOGY: 
Thyroid gland starts developing around 2nd or 3rd week of gestation 
and completes by 11th week and becomes functional at third month.1 
Thyroid gland develops from median endodermal thyroid diverticulum, 
which arises from foramen caecum, present between tuberculum impar 
and copula linguae in the base of the tongue. From foramen caecum, 
thyroglossal duct develops and descends down behind the hyoid bone to 
the neck. It lies in front of the trachea and bifurcates to form two lobes of 
thyroid gland. 
The thyroglossal duct then obliterates. Sometimes the lower end of 
thyroglossal duct may persist forming pyramidal lobe or Lalou ette’s 
pyramid.  Parafollicular or ‘C’ cells are derived from caudal pharyngeal 
complex or ultimobranchial body derived from fourth and fifth 
pharyngeal pouches.2 Solid cell nests, having collections of stratified 
epithelial cells with mucin production focally and cyst formation are the 
remnants of the ultimobranchial body and seen in 30% of adult thyroid. 
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On 9th week follicular cells are present as cords and plates. On 10th  
week follicular lumina appears and is small , by 12thweek colloid 
secretion begins and at 14th week well  formed follicles lined by cuboidal 
cells, containing colloid within the lumen are present . 
HISTOLOGY: 
Thyroid gland is covered by a  fibrous  capsule  and the  septa  
arising from it divides the gland into lobules. Each lobule is composed of 
many follicles of approximately 200µm in diameter. They are lined by 
follicular cells with central lumen containing colloid. The interstitium 
contains parafollicular  C cells, lymphatics and blood vessels. C cells are 
called as clear cells or light cells. They are polyhedral with eccentrically 
placed oval nuclei. 
The follicular cells vary in their shape depending upon their 
function. The normal cells are cuboidal, whereas the inactive or resting 
cells are flat to squamous and become columnar when hyperactive.3 
ANATOMY:                                                                                                                
 The normal thyroid gland weighs about 25 grams in adults and is 
slightly larger in females than males.4It has two lobes, the right and the  
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left  joined by isthmus. Each lobe measures about 5cm x 2.5 cm x 2.5 cm. 
Isthmus measures 1.2 cm x 1.2 cm. Each lobe extends from the middle of 
thyroid cartilage to fourth or fifth tracheal ring. The isthmus extends 
between second to fourth tracheal rings. 
Thyroid gland has both true and false capsule. True capsule arises 
from connective tissue of gland and false capsule from pre-tracheal 
fascia. Suspensory ligament of Berry connects the thyroid gland to 
cricoid cartilage, posteriorly. 
It has rich blood supply from superior thyroid artery, inferior 
thyroid artery, thyroidea ima artery in 3%of individuals, branches of 
tracheal and oesophageal arteries. Thyroid gland is drained by superior, 
middle and inferior thyroid veins. 
Lymphatic drainage is to the upper and lower deep cervical nodes, 
pre-tracheal and para-tracheal nodes. Nerve supply is from the middle 
cervical ganglion, mainly and small contributions from the superior and 
inferior cervical ganglia. 
PHYSIOLOGY: 
The thyroid gland plays important role in regulation of basal 
metabolic rate, calcium metabolism, somatic and psychic growth by the 
production of L- thyroxine -T4  and L – triiodothyronine  T3. T3 is more 
10  
potent than T4 (prohormone of T3). Thyroperoxidase is the primary 
enzyme of thyroid hormone synthesis. 
These hormones are regulated by negative feedback mechanism of 
hypothalamic-pituitary-thyroid axis. Thyrotrophin releasing hormone    
(TRH ) from hypothalamus, enters anterior pituitary gland and stimulates 
secretion of thyroid stimulating hormone  ( TSH ) which in turn acts on 
the thyroid gland, to produce and release T3 and T4. They bind to thyroid 
binding globulin (TBG) in plasma. Unbound forms are the active one in 
tissues. 
THYROID TUMORS - AN OVER VIEW: 
Thyroid tumors are the most common endocrine tumors. The 
estimated age standardized annual incidence is 1.0 to 2.9 cases per 1, 00, 
000 men and 3.4 to 9.1 cases per 1, 00, 000 women according to 
GLOBACON 2008. Thyroid tumors are more common in developed 
countries. The incidence of thyroid tumors has increased in past two 
decades, predominantly papillary carcinoma of thyroid.5The liberal 
criteria for diagnosis of papillary carcinoma of thyroid and detection of 
small tumors by imaging techniques and environmental factors led to 
increase in the incidence of thyroid tumors.6 
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RISK FACTORS FOR THYROID CARCINOMA : 
 Irradiation  to head and neck 
 Age : <20 or >45 years 
 Bilaterality 
 Female  gender 
 Iodine deficiency (follicular cancer) 
 Positive Family history   for  thyroid carcinoma  or MEN 2 
syndrome 
FEATURES INDICATING MALIGNANCY: 
 Extrathyroidal extension. 
 Fixation of nodules to adjacent soft tissues and structures. 
 Paralysis of vocal cord 
 Involvement of lymph nodes. 
 Nodule size > 4 cm. 
 Progressively enlarging neck mass. 
 
GENERAL CHARACTERISTICS OF PRIMARY THYROID 
CANCERS: 
1. Most common histologic type is papillary carcinoma.7 
2. Females are most commonly affected than men. 8 
3. Young patients have well differentiated tumors whereas in older 
patients less differentiated tumors are common. 
4. Young females below 40 years have slightly better prognosis 
than older individuals.9 
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5. Size of the primary tumor with staging is essential and is an 
important factor that determines the prognosis. 
 
CHARACTERISTIC FEATURES OF PRIMARY THYROID 
CARCINOMAS IN CHILDREN: 
1. Most common is papillary carcinoma of thyroid. National 
Cancer Institute in 2013 in their statistical analysis also found 
that  papillary carcinoma is common comprising 70-80%.10 
2. Radiation exposure plays important role, example : Hiroshima 
Nagasaki bomb explosion.11 
3. 60 – 80% of them present with lymph node metastasis and 
recurrence is more common in these patients.12 
4. Thyroid carcinomas in children, though aggressive has slightly 
good prognosis having mortality rate 2.6 % only. 
FAMILIAL THYROID TUMORS: 
25% of tumors occur in familial form, not only medullary 
carcinoma, but also familial non - medullary thyroid carcinoma can 
occur. 
Familial non-medullary thyroid carcinoma syndrome is diagnosed 
if three or more first degree relatives have non - medullary thyroid 
carcinoma derived from follicular cells13 
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Examples are: 
1. Familial papillary thyroid carcinoma with or without oxyphilia 
chromosome locus 19p13.2 (TCO). 
2. Familial papillary thyroid carcinoma with renal papillary 
neoplasia chromosome 1q21 (FPTC/PRN). 
3. Familial non- medullary thyroid carcinoma type –I chromosome 
2q21 (NMTC-1). 
4. Familial multinodular goiter syndrome chromosome 14q31 
(MNG – 1). 
SYNDROMES   ASSOCIATED   WITH   THYROID   TUMORS: 
S. 
NO SYNDROME 
GENE 
INVOLVED INCIDENCE THYROID TUMORS 
1. Familial 
adenomatous 
polyposis 
APC (5q21) 2-12% Papillary carcinoma 
cribriform - morular 
variant often 
2. PTEN- 
hamartoma 
tumour (Cowden 
syndrome ) 
PTEN 
(10q23.2) 
> 10% Follicular carcinoma, 
papillary carcinoma 
occasionally, benign 
follicular nodules 
3. Carney complex PRKAR1α 
(17q22-24) 
15% Follicular carcinoma, 
papillary carcinoma, 
benign follicular 
nodules 
4. Werner syndrome WRN (8p11-
12) 
18% Follicular carcinoma, 
papillary carcinoma, 
undifferentiated 
carcinoma, benign 
follicular nodules 
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WHO CLASSIFICATION (2004) OF PRIMARY THYROID 
TUMORS 
Tumors of thyroid follicular or metaplastic epithelium: 
1. Follicular adenoma (includes Hürthle cell adenoma) 
2. Papillary carcinoma 
3. Follicular carcinoma (includes Hürthle cell carcinoma) 
4.  Mucinous carcinoma 
5.  Mucoepidermoid carcinoma 
6.  Sclerosing mucoepidermoid carcinoma with eosinophilia 
7.  Poorly differentiated thyroid carcinoma 
8.  Anaplastic  / Undifferentiated carcinoma (including squamous cell 
carcinoma and carcinosarcoma) 
Tumors showing C-cell differentiation 
1. Medullary carcinoma 
Tumors showing both follicular and C-cell differentiation 
1. Collision tumor: follicular/papillary and medullary carcinomas 
2. Mixed medullary and follicular cell carcinoma 
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Tumors showing thymic or related branchial pouch differentiation 
1. Ectopic thymoma 
2. Carcinoma showing thymus-like element (CASTLE) 
3. Spindle epithelial tumor with thymus-like differentiation 
(SETTLE) 
Tumors of lymphoid cells  
1. Malignant lymphoma 
2. Extramedullary plasmacytoma 
Mesenchymal and other tumors 
1. Benign and malignant mesenchymal tumors such as solitary 
fibrous tumor, peripheral nerve sheath tumor, smooth muscle 
tumor, and angiosarcoma 
2.  Paraganglioma 
3.  Teratoma 
4.  Secondary tumor deposits in thyroid gland 
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Tumor, Node, Metastasis (TNM) Staging of Tumors of the 
Thyroid: 
TUMOR (T): 
TX   -  Primary tumor cannot be assessed 
T0 - No evidence of primary tumor 
T1 - Tumor ≤ 2cm in greatest dimension and limited to 
the thyroid 
T2 - Tumor >2 cm but <4 cm and limited to the thyroid 
T3   - Tumor >4 cm in greatest dimension and limited to 
the thyroid or tumor  with minimal  extrathyroid 
extension (e.g., extension to perithyroid soft tissues 
or  sternothyroid muscle) 
T4a -  Tumor of any size extending beyond thyroid capsule 
and invades subcutaneous tissue, larynx, trachea, 
esophagus or recurrent laryngeal nerve 
T4b - Tumor invades prevertebral fascia / encases carotid 
artery/ mediastinal vessels. 
  All Anaplastic carcinomas are considered T4 
tumors. 
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T4a -  Intrathyroidal anaplastic carcinoma - any size 
T4b - Extrathyroidal anaplastic carcinoma   - any size 
REGIONAL LYMPH NODES (N) : 
NX    - Regional lymph nodes cannot be assessed 
N0     - No regional lymph node metastasis 
N1a   - Metastasis to Level VI (pretracheal, paratracheal, and 
prelaryngeal/ Delphian lymph nodes) 
N1b - Metastasis to unilateral, bilateral or contralateral 
cervical or  Superior  mediastinal nodes. 
DISTANT METASTASIS (M) : 
MX   - Distant metastasis cannot be assessed 
M0 - No distant metastasis 
M1 - Distant metastasis present 
STAGE GROUPING 
Separate stage groupings are recommended for papillary (or) 
follicular, medullary and anaplastic carcinoma. 
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          Papillary or Follicular (<45 years) : 
Stage I       Any T  Any N  M0    
Stage II       Any T  Any N  M1    
Papillary or Follicular (45 years and older): 
Stage I          T1  N0  M0    
Stage II     T2  N0  M0    
Stage III       T3  N0  M0    
Stage III       T1  N1a  M0    
Stage III     T2  N1a  M0    
Stage III        T3  N1a  M0    
Stage IVA    T4a  N0  M0    
Stage IVA  T4a  N1a  M0 
Stage IV A    T1  N1b  M0 
   
Stage IVA           T2  N1b  M0    
Stage IVA              T3  N1b  M0    
Stage IVA        T4a  N1b  M0    
Stage IVB      T4b  Any N  M0    
Stage IVC      Any T  Any  N  M1    
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Medullary Carcinoma : 
Stage I                 T1  N0  M0    
Stage II              T2  N0  M0    
Stage III              T3  N0  M0    
Stage III                 T2  N1a  M0    
Stage III                 T2  N1a  M0    
Stage III                 T3  N1a  M0    
Stage IVA              T4a  N0  M0    
Stage IVA              T4a   N1a  M0    
Stage IVA              T1  N1b  M0    
Stage IVA              T2  N1b  M0    
Stage IVA              T3  N1b  M0    
Stage IVA              T4a  N1b  M0    
Stage IVB              T4a  N1b  M0    
Stage IVC   Any T    Any  N  M1    
Anaplastic Carcinoma : 
All anaplastic carcinomas are considered Stage IV 
Stage IVA         T4a  Any N  M0    
Stage IVB         T4b  Any N  M0    
Stage IVC         Any T  Any N  M1    
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ROLE OF IMMUNOHISTOCHEMISTRY IN THYROID 
LESIONS: 
 As   there  is  morphological overlap between many thyroid tumors 
with follicular pattern as seen in follicular adenoma, follicular carcinoma 
and follicular variant of papillary carcinoma and the  nuclear features 
characteristic of papillary carcinoma like nuclear grooves and inclusions 
are also seen in multinodular goiter with papillary hyperplasia and 
Hyalinising trabecular adenoma , immunohistochemistry is helpful in 
differentiating the tumors. A panel of immunomarkers that are useful 
includes Cytokeratin 19, HBME-1, galectin -3, CD 56, PAX 8 and Ret – 
oncoprotein. 
CYTOKERATIN 19: 
Cytokeratin 19 belongs to the keratin family. It is a 40 kDa protein 
that is encoded by KRT 19 gene in human being. It is an intermediate 
filament involved in protein binding, organization of myofibres and 
maintains structural integrity of epithelial cells. This acidic protein 
arranged in pair of  heterotypic  keratin  chains unlike its related family 
members is not paired with basic cytokeratin in epithelial cells. They are 
clustered in region of chromosome 17q12 - q21. 
              Cytokeratin 19 is widely applied as diagnostic marker of 
papillary thyroid carcinoma.14Hanan Alsaeid Alshenawy  in his study 
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found cytokeratin19 as a sensitive marker in diagnosis of papillary 
carcinoma and its variants.15It is also expressed in defined zone of basal 
keratinocytes, sweat gland, mammary gland ductal and secretory cells , 
GIT, ectocervix epithelium and urothelium. 
HBME-1: 
 
HBME-1 (Hector Battifora mesothelial ) is a monoclonal antibody 
which act against the antigen present on mesothelial cell membrane. It is 
named  after  Dr. Hector Battifora, who introduced this marker.The target 
epitope is located in microvilli. It is expressed in thyroid papillary and 
follicular carcinoma but is not expressed in nodular goiter or in nodular 
hyperplasia.16 
GALECTIN-3: 
Galectin-3 is a 31kDa protein belonging to the lectin family and is 
encoded by the gene LGALS3 located in chromosome 14 in the locus 
q21-q22. It binds to beta-galactosides and play important role in 
regulation of cell to cell or cell to matrix interaction, repair of cell 
damage and cell migration. Galectin-3 also plays an important role in 
neoplastic transformation and inflammation. It aids in distinguishing 
papillary carcinoma and follicular variant of papillary carcinoma from 
other follicular patterned nodules.17 
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CD 56: 
CD56, a neural adhesion molecule plays an important role in 
regulating migrating capabilities of neoplastic cells. Loss of CD 56 
expression leads to increase in metastatic potential of tumor cells and 
leads to poor prognosis. CD 56 is normally expressed by normal thyroid 
follicular epithelial cells. Low expression of CD 56 is useful in diagnosis 
of papillary carcinoma of thyroid.18 
PAX 8: 
PAX 8, a transcription factor is essential for the development of 
thyroid follicular cells and also expresses thyroid specific genes. It is 
expressed in papillary carcinoma, follicular neoplasms, medullary 
carcinoma and poorly differentiated carcinoma. It is also expressed in B 
cell lymphomas, renal cell carcinoma and normal B lymphocytes. 
RET ONCOPROTEIN: 
Ret gene play an important role in the production of tyrosine 
kinase, a  transmembrane receptor. Ret gene is located in chromosome 
10q. It is not expressed in normal thyroid follicular cells, but gene 
rearrangement commonly occurs in papillary carcinoma and hence useful  
in the diagnosis of papillary carcinoma, which is proved by the study 
conducted by Cheung et al.19 
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BENIGN THYROID NODULES: 
It is classified as hyperplastic nodules and benign epithelial 
neoplasm.  Hyperplastic  nodules includes dyshormonogenetic goiter 
and nodular hyperplasia. Benign epithelial tumors are follicular 
adenoma and hyalinising trabecular adenoma. 
DYSHORMONOGENETIC GOITER: 
It occurs due to defect in hormone synthesis  due to peroxidase 
deficiency, deiodinase deficiency, defective iodide transport, defective 
coupling, decreased thyroglobulin synthesis and loss of function of 
pendrin gene ( ion channel for transport of iodine).20 Thyroid gland is 
grossly enlarged and multinodular.  Microscopically it may show 
microfollicular, solid, papillary and insular pattern. Marked nuclear 
atypia of cells inbetween hyperplastic nodules and increased mitoses are 
seen. Follicular carcinoma and papillary microcarcinoma are incidental 
findings.21T4 replacement therapy can produce thyroid tumors in these 
patients. 
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NODULAR HYPERPLASIA: 
It is also called as multinodular goiter or adenomatous goiter or 
adenomatous hyperplasia. It exists in two forms, endemic and sporadic 
goiter. Endemic goiter occurs in geographical areas with low iodine 
content in soil and water leading to defective thyroid hormone synthesis 
which stimulates TSH release and causes diffuse or nodular colloid 
goiter. 
Sporadic goiter is due to dietary deficiency of iodine or increased 
excretion of iodine by kidney or defective hormone synthesis by 
antibodies. In both, thyroid gland is enlarged and has multiple nodules 
surrounded by complete or incomplete capsule. Few dilated follicles have 
conglomerate of small follicles at one pole which are active called as 
Sanderson polsters. 
Some follicles are cystically dilated with papillary hyperplasia and 
the papillae face towards the center of the cyst which may mimic 
papillary carcinoma24. Nuclear atypia is seen in cells within nodules due 
to previous irradiation incontrast to dyshormonogenetic goiter where it is 
seen inbetween hyperplastic follicles. It is also different from adenoma 
which is solitary and completely encapsulated. Chromosomal 
abnormalities are rare and may have TSHR mutations, extra copy of 
chromosome 7 and RAS mutations.22 
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FOLLICULAR ADENOMA: 
Follicular adenoma is a solitary benign encapsulated tumor and the 
patients are in euthyroid state. In radioactive iodine scan, usually 
follicular adenoma is cold, at times, warm and rarely hot. Hot nodules 
indicate benign lesion. 
PLUMMER ADENOMA : 
Follicular adenoma with hyperthyroidism is called as toxic 
adenoma or PLUMMER ADENOMA.23Plummer adenomas have 
activating mutation of TSHR or GNAS1. Intra luminal calcium oxalate 
crystals present in thyroid follicles, with hyperfunctioning nodule outside 
is a sign of hypofunction. Mitosis is rare. Secondary degenerative changes 
like hemorrhage, cystic degeneration and fibrosis are common. 
Some follicular adenoma have papillary structures reported as 
papillary adenoma in past which gave confusion with papillary carcinoma 
is now termed as follicular adenoma with papillary architecture.24 
Follicular adenoma has four different patterns: 
1)  Normofollicular / simple type 
2)  Microfollicular / fetal type 
3)  Macrofollicular / colloid type 
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4)  Trabecular /embryonal / solid type 
Rarely, papillary pattern can occur. 
DIFFERENTIAL DIAGNOSIS OF LARGER FOLLICLES: 
1) Hyperplastic nodule 
2) Follicular variant of papillary carcinoma 
DIFFERENTIAL DIAGNOSIS OF SOLID / TRABECULAR / 
NESTED PATTERN: 
1)  Medullary carcinoma 
2)  Poorly differentiated carcinoma 
But they are mostly invasive. Calcification, edema and bone 
formation are more common. 
IMMUNOHISTOCHEMISTRY OF FOLLICULAR ADENOMA: 
1)  Low molecular weight keratin - cytoplasmic positivity 
2)  TTF 1- nuclear positivity. 
3)  Laminin is positive around follicles.25 
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MOLECULAR GENETICS: 
            No molecular test effectively distinguish follicular adenoma from 
follicular carcinoma because both has similar chromosomal abnormalities 
like activating RAS stimulation, PAX 8 / PPARγ rearrangement.26 
Other Chromosomal abnormalities specific for follicular adenoma - 
are translocations involving Chromosomes 19q13 having break point at 
ZNF 331 gene locus and chromosome 2p21 - break point at (THADA) 
thyroid adenoma associated gene locus.27Sporadic follicular adenoma has 
rarely alteration of  PI3K /  PTEN/  AKT pathway. 
VARIANTS OF FOLLICULAR ADENOMA: 
1)  Hurthle cell adenoma. 
2)  Hyalinizing trabecular adenoma. 
3)  Atypical adenoma – has irregular cytoarchitecture but, lacks 
capsular and vascular invasion.28 
4)  Adenoma with bizzare nuclei- cells occur in clusters and have huge 
hyperchromatic nuclei. Other malignant features are absent. 
5)  Clear cell type 
6)  Adenolipoma  
7)  Adenochondroma    - adenoma having cartilaginous metaplasia 
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8) Spindle cell adenoma - resembles meningioma somehow. 
9)  Black adenoma - minocycline induced.29 
TREATMENT: 
 Lobectomy 
 Levothyroxine to suppress the nodule  and 
 I131 for toxic adenoma. 
HYALINIZING TRABECULAR ADENOMA: 
It was first identified by Langhans and the term given by 
Carney.30 
MICROSCOPY: 
Tumor cells are arranged in trabecular pattern. Cytoplasm shows 
prominent hyaline material due to intermediate filament accumulation 
which is also present in extracellular matrix. Hyalinised collagen and 
basement membrane material are present. 
Cytoplasmic yellow body - pale yellow inclusion bodies situated 
near nucleus with refractile quality is present.31 Psammoma bodies, 
nuclear grooves and nuclear pseudo inclusions are seen. 
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IMMUNOHISTOCHEMISTRY: 
Thyroglobulin and TTF -1 is strongly positive, galectin -3 in half of 
cases and   NSE and neurotensin – only focally positive. 
Pathogenetic link between hyalinising trabecular adenoma and 
papillary carcinoma: 
 Both Papillary carcinoma and hyalinising trabecular adenoma 
have nuclear grooves, nuclear pseudoinclusions and psammoma 
bodies. 
 Both express epithelial type keratins.  
 Hyalinising trabecular adenoma can have foci of papillary 
carcinoma. 
 Papillary carcinoma with hyalinising trabecular adenoma like 
pattern with cervical node metastasis is seen. 
 Both have RET/PTC rearrangement. 
 Because  of  the overlapping features it is now termed as 
Hyalinising trabecular tumor.32 
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HURTHLE CELL OR ONCOCYTIC TUMORS: 
HURTHLE CELL ADENOMA: 
It is common in female adults .Tumors are solid, tan, encapsulated 
and has rich vascularity. The tumor cells have follicular, papillary, 
trabecular or solid pattern and has inspissated colloid having concentric 
laminations. Cells have deeply eosinophilic, granular cytoplasm.  Nuclei 
sometimes exhibit pleomorphism and may have prominent nucleoli. Few 
bizarre forms are also seen. But they do not indicate malignancy. Most of 
them are benign and show reactivity for thyroglobulin. Benign tumors are 
called as Hurthle cell adenoma. 
ATYPICAL HURTHLE CELL ADENOMA: 
             It is also called as Hurthle cell tumors of uncertain malignant 
potential (HCT-UMP) .They have solid or trabecular pattern of growth 
with increased nuclearcytoplasmic ratio. There is no capsular or vascular 
invasion and does not metastastize  to other sites. 
HURTHLE  CELL CARCINOMA: 
They are aggressive tumors and have solid pattern of growth, 
increased mitoses and have capsular and/or vascular invasion. They 
metastatise to bone and lungs. These tumors exhibit aneuploidy and 
chromosomal gain at 20p and 19q. 
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Hurthle cell tumors commonly undergo acute infarction following 
fine needle aspiration. Hurthle cell tumors >4 cm have poor prognosis. 
MALIGNANT THYROID TUMORS: 
PAPILLARY CARCINOMA: 
            It is the most common primary thyroid carcinoma and affects any 
age with mean age of 40 years having female preponderance. In children, 
90% of thyroid malignancy is constituted by papillary carcinoma. 
Irradiation to head and neck causes papillary carcinoma in 5 -10 % of 
cases and can arise in patients with Hashimoto’s thyroiditis.  
            Papillary carcinoma in thyroid gland alone is 67%, Thyroid and 
cervical nodes - 13%, Lymph nodes alone -20%.33 
GROSS APPEARANCE: 
         Size varies from microscopic to larger nodule and most of the 
tumor nodules are < 1 cm. Grossly it appears as infiltrating nodule 
with ill - defined border and is grey white to tan and granular. 
Encapsulated variant has thick capsule and constitutes < 10%.34 
Calcification and psammoma bodies give gritty feel while cutting. 
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MICROSCOPIC FEATURES: 
Papillary carcinoma consist of numerous branching papillae having 
central  fibrovascular core and lined by stratified cuboidal cells having 
characteristic nuclear features like Ground glass appearance / orphan 
annie nuclei / optically clear with nuclear overlapping, nuclear 
pseudoinclusions (round acidophilic vacuoles due to cytoplasmic 
invagination into nucleus ) and nuclear grooves along the long axis of 
nucleus due to infolding of redundant nuclear membrane and nuclear 
microfilament.59 
Psammoma bodies are seen in papillary stalk or between tumor 
cells or in fibrous stroma. Psammoma bodies are concentric lamellated 
basophilic structures occurring as a result of calcification of individual 
necrotic tumor cells and should be distinguished from inspissated 
secretions in Hurthle cell tumor. 
VARIANTS OF PAPILLARY CARCINOMA: 
1) PAPILLARY MICROCARCINOMA: 
        It is usually ≤1 cm in diameter, formerly called as occult 
sclerosing carcinoma or non - encapsulated sclerosing tumor. It is most 
common in males.36 RET / PTC rearrangements and BRAF mutations 
are common and has excellent prognosis. 
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2) ENCAPSULATED VARIANT: 
Tumor nodule is completely encapsuled. 
D /D: Hyperplastic nodule with central cystic degeneration which 
appears hot on thyroid scan and their papillae face towards the centre of 
cystic cavity and has pale vacuolated colloid. Immunohistochemistry 
shows negativity with high molecular weight keratin. 
3) FOLLICULAR VARIANT: 
Tumor cells are arranged in follicles and is invasive. Psammoma 
bodies, colloid with scalloped margins, abortive papillae and distinctive 
nuclear features are present. Follicular variant of papillary carcinoma has 
many types like solid variant, macro follicular variant, diffuse / 
multinodular variant and encapsulated variant called as LINDSAY 
TUMOR.37 
4) DIFFUSE SCLEROSING VARIANT: 
 It involves one or both lobes of thyroid gland. Dense sclerosis, 
solid foci, psammoma body, squamous metaplasia and lymphocytic 
infiltration are present.38 Lymph node and brain metastasis are common. 
 They exhibit both RET/PTC1 and RET/ PTC3 rearrangements.  
BRAF  mutation occur rarely. 
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5) ONCOCYTIC / OXYPHILIC VARIANT: 
 Tumor cells have abundant granular eosinophilic cytoplasm with 
papillary or follicular pattern with nuclear features of papillary 
carcinoma.39  It has good prognosis. 
6) TALL CELL AND COLUMNAR CELL CARCINOMA: 
 Tall cell variant has single layer of tall cells whose height is equal 
to three times the breadth.40 It has papillary structures, nuclear 
pseudoinclusions and lymphocytic infiltration of stroma. It is more 
aggressive and affects older age group. Extrathyroidal extension is 
common. 
Columnar cell carcinoma has stratified layer of columnar cells, 
with subnuclear  vacuolation and papillary carcinoma nuclear features are 
present. It has high proliferative index and has poor prognosis. 
7) CRIBRIFORM MORULAR VARIANT: 
It has cribriform growth pattern with morular formation. 
Ultrastructurally - accumulation of microfilaments made of biotin leads to 
nuclear clearing and is different from papillary carcinoma with strong 
nuclear and cytoplasmic positivity with β-catenin.41 
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8) PAPILLARY CARCINOMA WITH EXUBERANT NODULAR 
FASCITIS LIKE STROMA: 
It has prominent stromal reaction giving, fibroadenoma like 
appearance. It resembles nodular fasciitis and fibromatosis.42 
MOLECULAR GENETICS: 
Mitogen activated protein kinase pathway which regulates cell 
proliferation differentiation and survival plays major role in causation of 
papillary carcinoma. MAPK - pathway activation leads to RET/PTC 
rearrangements, TRK rearrangements, BRAF mutation and RAS 
mutation in follicular cells of thyroid. These mutations are mutually 
exclusive. 
REARRANGEMENTS: 
Gene rearrangements constitute 20 - 40% of papillary carcinoma. 
RET oncogene present in chromosome 10q11.2 is a transmembrane 
tyrosine kinase receptor , the point mutations of which causes medullary 
carcinoma and rearrangements causes papillary carcinoma. RET 
rearrangements occurs in intron 11 by intrachromosomal inversions 
involving long arm of chromosome 10, interchromosomal translocations. 
RET fuses with 12 different genes leading to 17 different chimeric 
sequences. 
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RET/PTC1 (RET fusion with CCDC6 a.k.a H4 or D10S170), 
RET/PTC3 (RET fusion with ncoa4 a.k.a, RFG, ELE1 or ARA 70), these 
two occur by intrachromosomal rearrangements and are more common. 
RET/PTC2 (RET fusion with PRKAR-1A, gene which is inactivated in 
patients with Carney complex) occurs in one third of the cases. Other 
mutations are rare. 
RET/PTC is common in children and young adults and those 
exposed to radiation.43 These rearrangements occur in classical papillary 
carcinoma or microcarcinoma. They represent low stage with little 
proliferative capability and less likely to undergo dedifferentiation. These 
features are more commonly seen in RET/PTC1 rearrangement. 
RET/PTC3 may behave aggressively. These rearrangements can be 
detected by reverse transcriptase polymerase chain reaction or by 
fluorescent in situ hybridization. 
BRAF: 
BRAF activating mutations are the most common genetic alteration 
constituting 30-70% of papillary carcinoma. It belongs to RAF family and 
is a serine threonine kinase of MAPK pathway. Most common molecular 
alteration is thymidine to adenine transversion in nucleotide 1799 of exon 
15 which leads to valine to glutamate substitution in residue 600 of 
protein activation loop. 
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BRAF mutations are  more specific for papillary carcinoma of 
thyroid and is present in papillary carcinoma arising in struma ovarii.  
BRAF mutation is characteristically present in tumors with papillary 
architecture. It is uncommon in follicular variant of papillary carcinoma. 
Other rare mutations of BRAF are K601E mutation, paracentric inversion 
of chromosome 7 and small deletions near codon 600. 
BRAF mutations have been attributed to male sex, older age group, 
extrathyroidal extension, metastasis to lymph nodes and distant sites, 
recurrence, high tumor stage at initial presentation and reduced survival. 
BRAF mutation are reduces gene expression required for enzymes 
production in thyroid hormone synthesis and it makes the tumor 
refractory to treatment radioactive iodine. 
RAS: 
          RAS mutations are seen in follicular patterned thyroid tumors like 
follicular adenoma, follicular carcinoma, follicular variant of papillary 
carcinoma.44 
NTRK1: 
NTRK1 gene encodes a transmembrane tyrosine kinase receptor 
and it binds with nerve growth factor. NTRK1 rearrangements constitute 
5% of papillary carcinoma. It causes inter and intrachromosomal 
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recombination at NTRK locus in chromosome 1q22 producing chimeric 
oncogene leading to spontaneous activation of NTRK1 tyrosine kinase. 
METASTASIS: 
Cervical lymph nodes are commonly involved with cystic 
degeneration.  It is commonly seen in young patients .Blood borne 
metastasis is less frequent and involves lungs, bone, soft tissue, central 
nervous system, breast and pancreas. In lung the metastatic foci appear as 
miliary micronodules and this can be identified with I131 scintiscan. 
Occasionally tumor spreads to nearby parathyroid glands. 
PROGNOSIS: 
• Good prognostic factors: 
• Children and adults < 40 years45 
• Females and 
• Encapsulated variant.46 
• Bad prognostic factors: 
• Age is > 40 years 
• Extra thyroid extension 
• Increasing size of tumor 
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• Multicentric tumor 
• Tumors with distant metastasis 
• Poorly differentiated and anaplastic carcinoma 47and 
• Tumors with aneuploidy and BRAF mutations.48 
IMMUNOHISTOCHEMISTRY: 
Cytokeratin 19, high molecular weight keratin demonstrated by     
34βE12, thyroglobulin and TTF -1 are strongly positive.49 Other markers 
are  TTF-2, PAX8, S 100, HBME-1, galectin 3, CD 15, CD 57, EMA, 
CEA, antichymotrypsin, insulin like growth factor, HER2/neu ,                                             
c-Met/hepatocyte  growth factor receptor and vimentin. 
FOLLICULAR CARCINOMA: 
Follicular carcinoma, a rare neoplasm of elderly females 
predominantly constitutes 10 – 18 % of all the primary thyroid tumors. It 
is identified by the capsular or vascular invasion or invasion of adjacent 
thyroid.50 
It arises commonly in patients with endemic goiter and iodine 
deficiency. Rarely, it arises from follicular adenoma. Irradiation and 
dyshormonogenesis also predispose to follicular carcinoma 
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GROSS EXAMINATION: 
Follicular carcinomas is solid tan to light brown fleshy, sometimes 
glistening with, areas of hemorrhage and cystic degeneration .Minimally 
invasive variant are encapsulated. Size varies from 1cm to 10 cm. 
MICROSCOPIC FEATURES: 
Follicular carcinoma has thick fibrous capsule in which the tumor 
cells are arranged in closely packed follicles, trabecular pattern or solid 
sheets. The tumor cells are cuboidal to low columnar and have round 
nuclei with inconspicuous nucleoli sometimes exhibiting, nuclear 
pleomorphism. Mitosis is uncommon. Vascular invasion and capsular 
invasion are the diagnostic features and it   differentiates follicular 
adenoma from follicular carcinoma. 
VARIANTS  (based on invasion ): 
1) Minimally invasive follicular carcinoma.51 
2) Widely invasive follicular carcinoma.52 
MINIMALLY   INVASIVE FOLLICULAR CARCINOMA: 
It is encapsulated variant resembling follicular adenoma of 
embryonal or fetal type. Invasion into vessels of venous caliber within or 
outside the capsule should be present. Tumor cells are attached to the 
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wall of  vessels  lined by endothelium or protrudes into lumen. CD31, 
Ulex europaeus, Factor –VIII related antigen and Fli –I   endothelial cells 
marker are useful. Capsular invasion should be present and 
pseudoinvasion has to be ruled out. Pseudoinvasion  is due to herniation 
of tumor tissue due to breech in capsule made by surgeon on fresh 
specimen. 
TERMS USED IN FOLLICULAR NEOPLASM: 
 Follicular carcinoma – tumors with definite capsular invasion 
 Follicular tumor of uncertain malignant potential – has 
questionable capsular invasion but does not have nuclear features 
of papillary carcinoma. 
 Well differentiated tumors of uncertain malignant potential – has 
questionable nuclear changes (? Papillary carcinoma type) 
WIDELY INVASIVE FOLLICULAR CARCINOMA: 
Tumors that are encapsulated and having four or more blood vessel 
invasion or those having wide spread infiltration into blood vessels and / 
or adjacent thyroid tissue are termed as widely invasive follicular 
carcinoma. Metastasis to sternum, shoulder girdle, skull and iliac bone is 
common. Those tumors that look alike normal thyroid tissue is called as 
metastasizing adenoma / metastasing goiter/ malignant adenoma and 
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has affinity for radioiodine.53 < 5% of minimally invasive type of tumors 
have metastasis. 
MOLECULAR GENETICS: 
1. Castro and Colleagues postulated that chromosomal gains and 
aneuploidy leads to microfollicular/ solid / trabecular pattern. Diploidy 
and near diploidy forms normofollicular  pattern.  
2. Loss of heterozygosity, (LOH) of 20% per chromosomal arm produce 
follicular carcinoma and only 5% loss occurs in follicular adenoma 
and codon 12 and 13 of K-RAS occurs in follicular carcinoma.54 
3. PAX 8/ PPAR gamma rearrangement due to t (2:3) (q13; p25) is 
common in females, young age, highly cellular and invasive tumors.55 
4. PI3K / PTEN /AKT pathway activation is common in COWDEN 
SYNDROME, CARNEYS COMPLEX I and WERNER SYNDROME .56 
5. TSHR gene mutations are rare and occurs in hyperfunctioning 
follicular carcinoma 
6. VEGFR1 genes are also involved. 
POORLY DIFFERENTIATED CARCINOMA: 
Tumors falling in between well differentiated and anaplastic type 
are the poorly differentiated carcinoma .INSULAR CARCINOMA is the 
one commonly seen, arising from follicular carcinoma.57Papillary 
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carcinoma can also progress to poorly differentiated carcinoma. It is 
common in old age about 60 years. Recurrence, extrathyroidal extension 
and metastasis to lymph nodes (14 – 48 %) and distant sites (12-44%) are 
common. Mortality rate is increased to 50%. TP53 mutation and β catenin 
mutations are common.58Insular carcinoma analogous to “Langhans’ 
wuchernde struma “   is common in South America and Europe. 
Gross and Microscopic Appearance: 
The tumor is solid grey white, partly encapsulated or invasive with 
areas of hemorrhage and necrosis. Microscopically the tumor cells are 
arranged in insular pattern with retraction artifact or as diffuse sheets. 
Coagulative necrosis giving peritheliomatous appearance is common.59 
Tumors cells are small with vesicular or hyperchromatic nuclei and 
vascular invasion is commonly seen. Tumor cells are positive for TTF-1 
and PAX8 and have increased   Ki-67 index. 
UNDIFFERENTIATED / ANAPLASTIC CARCINOMA: 
Anaplastic carcinoma constitutes 2-5% of primary thyroid cancers. 
Women of >70 years are commonly affected. They are aggressive tumors 
growing rapidly in a shorter period with increased incidence of recurrence 
and metastasis. Most of the patients die within a year. 
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Tumor cells produce granulocyte colony stimulating factor causing 
marked increase in leucocytes. They are resistant to chemotherapy. 
Younger patients with tumors < 4 cm can be operated with radical 
surgery along with adjuvant chemoradiation. 
They have mutation in TP53 gene (70%), β-catenin mutation 
(65%), RAS mutation (30%)   mutations in BRAF and RET/ PTC, PTEN, 
APC, PIK3CA and APC. 
GROSS AND MICROSCOPIC FEATURES:        
Grossly tumor completely replaces entire thyroid gland and 
invades surrounding soft tissue. Microscopically cells are either of 
squamoid type or sarcomatoid type – having spindle cells and giant cells.  
Epithelial looking cells are arranged in sheets and large polygonal with 
highly pleomorphic nuclei and many giant cells and bizarre forms are 
seen. Spindle cell components are alike to undifferentiated pleomorphic 
sarcoma, with extensive necrosis and hemorrhage. 
VARIANTS: 
 Angiomatoid variant 
 Osteoclastic variant 
 Rhabdoid variant 
 Lymphoepithelioma like carcinoma 
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 Paucicellular  variant 
 Carcinosarcoma 
 Adenosquamous carcinoma 
 Squamous cell carcinoma 
Immunohistochemistry: 
Cytokeratin positivity is variable (47-90%) depending on 
proportion of carcinoma component antigen and PAX8 (76%).61 
MEDULLARY CARCINOMA: 
           Medullary carcinoma is a malignancy with parafollicular C cell 
differentiation. It may be sporadic or part of familial or multiple 
endocrine neoplasia 2A or 2B.62 Sporadic form is common in 44- 50 
years, and around 10-30 years in MEN syndrome. In sporadic form 
bilateral tumors are 0-32%, 40-50% of nodal metastasis and 12% of 
distant metastasis with intermediate prognosis. Hereditary medullary 
carcinomas have autosomal dominantly acquired RET proto-oncogene 
mutation and 90% are bilateral tumors. 
Familial and MEN-2A associated medullary carcinoma have 
indolent course with mutation in exon 10, 11, 13, 14 or 15. MEN 2B 
incur mutation at exon 16 (ATG  ACG; methionine to threonine) and 
has aggressive course. Other tumors in MEN 2A are Pheochromocytoma, 
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parathyroid tumors and cutaneous lesions; MEN 2B Pheochromocytoma, 
neuromas of mucosa and intestine and Marfanoid features. Lymph node 
metastasis is 10 – 30 % in hereditary form with metastasis to distant sites 
rarely except MEN 2B (38%). 
Grossly the tumor is small firm, greywhite to tan or reddish brown 
.Tumor is most commonly present in middle third of lateral lobe because 
of increased C cell number there. They may have capsule. Larger tumors 
have necrosis and hemorrhage. Microscopically tumor cells are arranged 
in nest, sheet, trabecular, tubular, pseudopapillary, cribriform or 
microglandular pattern. Cells are round to polygonal cells having 
amphophilic cytoplasm with round nuclei having stippled chromatin. 
Nuclear pleomorphism and mitoses are infrequent. Increased vascularity 
is a striking feature.80-85% of cases have amorphous eosinophilic 
material called as amyloid.63 
VARIANTS: 
 Glandular / follicular type 
 Oncocytic / oxyphilic type 
 Pseudopapillary type 
 Clear cell type, small cell type , pigmented variant 
 Spindle cell type ,Giant cell variant, 
 Paraganglioma like, neuroblastoma like variant 
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 Pseudoangiosarcomatous like , carcinoid like 
 Hyalinising trabecular adenoma like 
Immunohistochemistry: 
Tumors show strong positivity with cytokeratin, pan-
neuroendocrine markers, TTF1, calcitonin, CEA- (80 -100%). 
Amyloid can be stained with congo-red and under polarized light 
gives apple green birefringence. 
PROGNOSTIC FACTORS: 
 GOOD prognosis: 
 Female sex 
 Medullary carcinoma in MEN 2A64 
 Medullary microcarcinoma (<1 cm) and 
 Small tumors. 
 BAD prognosis: 
 Above  45 years of age 
 MEN 2B associated medullary carcinoma 
 Small cell type 
 Calcitonin poor tumors65 and 
 Tumors with somatic RET proto-oncogene mutation.66 
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MUCOEPIDERMOID CARCINOMA: 
 Primary mucoepidermoid carcinoma is a low grade malignant 
neoplasm which is rare.67 Females are commonly affected around 10-83 
years of age . 20% of the individuals presented with thyroid mass having 
extrathyroidal extension. Lymph  node  metastasis  occur commonly but 
distant metastasis is rare. 
Harach stated “Mucoepidermoid carcinoma of thyroid arises from 
ultimobranchial body”.68 Some other study insisted as tumor of 
thyroglossal duct origin. 
Histologically the tumor is not circumscribed and has cellular 
islands present in a sclerotic background.some of the cells contain 
intracytoplasmic mucin. Few of the cells are squamoid. Comedo type of 
necrosis, nuclear pleomorphism and psammoma bodies are present. 
Rarely glands that are lined by ciliated columnar epithelium is seen.  
Mucoepidermoid carcinoma can occur along with papillary 
carcinoma.two cases of mucoepidermoid carcinoma associated with 
follicular carcinoma (Hurthle cell variant) are also on record.69 
IMMUNOHISTOCHEMISTRY: 
Thyroglobulin and TTF-1 are positive. 
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SCLEROSING MUCOEPIDERMOID CARCINOMA WITH 
EOSINOPHILIA: 
 It is a rare tumor of low grade malignant behavior and occurs in a 
background of Hashimoto thyroiditis.70 It arises from metaplastic  
squamous epithelium. It is common in adults with mean age of 55 years 
and with female preponderance. It is an aggressive tumor.71 
Tumor is composed of nests and anastomising cords of cells in a 
dense sclerotic stroma which is infiltrated with eosinophils and 
lymphocytes. Tumor is infiltrative and it extends to perithyroidal tissue. 
Cells are polygonal with mild to moderate nuclear pleomorphism with 
prominent nucleoli. Some foci show squamoid nests and mucin pools. 
Perineural invasion and blood vessel obliteration are common. Lymph 
node metastasis resembles Hodgkin lymphoma.72 
IMMUNOHISTOCHEMISTRY: 
CYTOKERATIN AND TTF-1 are positive in these tumors. 
MUCINOUS CARCINOMA: 
 Primary mucinous carcinoma is very rare in thyroid .Only seven 
cases have been reported in literature.73 these tumors metastatize rapidly 
with mean survival of about 6 months to 4 years. It is similar to colloid 
carcinoma occurring in other sites. 
 Immunohistochemistry show thyroglobulin and TTF-1 positivity. 
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TUMORS SHOWING DIFFERENTIATION OF BOTH 
FOLLICULAR AND C-CELL : 
COLLISION TUMORS: 
 Collision tumors are composed of two recognizable types of 
carcinoma of thyroid. They are 
1. Medulllary carcinoma and follicular carcinoma74,75 
2. Papillary carcinoma and medullary carcinoma76 
They   occur   contiguously  and  are more  aggressive.  
MIXED MEDULLARY CARCINOMA AND FOLLICULAR CELL 
CARCINOMA: 
              It is also called as Follicular-parafollicular carcinoma or 
differentiated carcinoma of intermediate type.77This rare tumor arises 
from stem cells hence showing dual component. They are not capsulated. 
They have features of medullary carcinoma along with follicles. Other 
patterns like nests, cribriform, trabecular and solid pattern are also seen. 
Amyloid is present in few cases. These cells show neurosecretory 
granules, cells having intermediate features, follicular cells and 
indifferent cells ultrastructurally. 
Immunohistochemistry : 
Thyroglobulin and calcitonin positivity is present. 
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TUMORS OF HEMATOLYMPHOID CELLS: 
MALIGNANT LYMPHOMA: 
 Primary thyroid lymphomas, constitutes 2.5 to 3% of extranodal 
lymphomas and comprises 4 to 5 % of thyroid malignancies. It commonly 
occurs in elderly females. Lymphomas, commonly arises from 
lymphocytic thyroiditis or Hashimoto thyroiditis. Thyroid lymphomas 
form non -circumscribed rubbery or soft mass. Cut surface bulges out and 
is fleshy homogeneous and light tan coloured. Size of the tumor may vary 
from 1 to 14 cm. 
                 Non Hodgkin lymphomas are common in thyroid than 
Hodgkin lymphoma. Diffuse large B-cell lymphoma (constitute 70%) and 
extranodal marginal zone lymphoma of MALT type  occur most 
commonly.78 Follicular lymphoma and Burkitt lymphoma are very rare.79 
Some cases of intravascular large B cell lymphoma  and T cell lymphoma 
that expressing γδ  receptors of T cells are reported. 
METASTATIC MALIGNANT TUMORS IN THYROID: 
             As thyroid has rich blood supply and lymphatics invasion or 
metastasis to thyroid is common. Tumors like lung adenocarcinoma, 
colorectal carcinoma, renal cell carcinoma, malignant melanoma, breast 
carcinoma and sarcoma metastatize to thyroid gland.80 Sometimes 
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psammoma bodies can be seen in metastatic deposits giving 
misconception with papillary carcinoma.81 
              Metastatic neuroendocrine carcinoma from intra-abdominal site 
and bronchus present as solitary or multiple nodules within the thyroid 
gland giving misinterpretation as medullary carcinoma. The metastatic 
carcinomatous deposits usually present as multiple nodules with 
increased vascularity and hemorrhage. Immunohistochemistry with 
appropriate markers is useful in differentiating the tumor. 
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MATERIALS AND METHODS 
Study Design: 
Prospective study 
Study Period: 
From July 2014 – July 2015 
Study Place: 
Coimbatore   Medical   College and  Hospital, Coimbatore. 
Sample Size: 
A total number of  30 cases. 
From case records brief clinical data were collected, which included age, 
sex,  clinical diagnosis  and  surgical procedure . 
The following inclusion and exclusion criteria were adopted. 
Inclusion  Criteria : 
1. All thyroidectomy specimens  (hemithryoidectomy, subtotal and near 
total thyroidectomy  and  total thyroidectomy) done for solitary 
nodule or multiple neoplastic nodules. 
2. Patients in all age groups 
3. Both male and female patients 
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Exclusion criteria: 
 Multinodular goiter 
 Toxic goiter 
Methods: 
Among  the  total  thyroidectomy specimens that were   received in 
the department of  Pathology in our  hospital during the study period, 30 
cases  were taken into study as per inclusion criteria  and  were  evaluated 
further .  
         All those 30 thyroidectomy specimens (one with lymph node 
metastasis) selected were then fixed in 10% formalin, embedded in 
paraffin and stained with hematoxylin and eosin. 
HEMATOXYLIN AND EOSIN STAINING METHOD: 
REAGENTS USED: 
1.  Hematoxylin solution- Erhlich’s hematoxylin 
2.  Eosin Y 1% solution 
3.  Acid alcohol 1% solution 
PROCEDURE: 
1. Deparaffinize sections in xylene by immersing for 30 seconds. 
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2. Place the sections in Isopropyl alcohol for 15 minutes. 
3. Wash in running tap water. 
4. Stain in Erhlich’s hematoxylin for 10 to 15 minutes. 
5. Differentiation is done with 1% acid alcohol two to three dips. 
6. Blueing is carried out for 10 minutes. 
7. Counterstain with eosin 1% solution 3 to 4 dips. 
8. Running tap water wash. 
9. Air dry 
10. Mount with DPX 
      After hematoxylin and eosin staining, all slides were reviewed by 
pathologist and categorized as following 
1. Follicular  adenoma 
2. Minimally invasive Follicular carcinoma. 
3. Widely invasive follicular carcinoma 
4. Papillary carcinoma 
5. Follicular variant of papillary carcinoma 
The age group varied between 19 to 60 years. 
Follicular adenoma: 
       Follicular tumors that are completely encapsulated having 
homogeneous architecture and morphology are diagnosed as follicular 
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adenoma and those showing cystic spaces are called as follicular 
adenoma with cystic degeneration. 
Follicular carcinoma: 
       MINIMALLY  INVASIVE  follicular carcinoma are encapsulated 
tumors and are diagnosed based on following criteria: 
1. Tumors showing capsular invasion only. 
2. Tumors showing invasion into less than four blood vessels. They have 
low metastatic potential. 
3. Tumors showing invasion into four or more blood vessels. These 
tumors have higher metastatic potential. 
WIDELY INVASIVE follicular carcinomas are diagnosed by 
widespread invasion into thyroid parenchyma and also the blood vessels. 
These tumors may lack complete encapsulation. These tumors present 
with distant metastasis and regional lymph nodes involvement at initial 
presentation. They invade into surrounding soft tissues and has poor 
prognosis. 
Papillary carcinoma: 
 Papillary carcinoma is diagnosed based on the major and minor 
features. 
Major features are: 
 Ovoid nuclei 
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 Nuclear crowding 
 Nuclei having clear or fine chromatin 
 Psammoma bodies 
       Minor features are: 
 Abortive papillae 
 Dark colloid 
 Irregular follicles 
 Nuclear pseudoinclusions 
 Multinucleated histiocytes in the lumen of the follicles. 
Follicular variant of papillary carcinoma: 
           Tumor composed of follicles almost entirely (99%) with nuclear 
features of classic papillary carcinoma. 
PROCEDURE OF IMMUNOHISTOCHEMISTRY: 
The blocks from control and selected cases were cut and mounted on 
poly l- lysine coated glass slides. Blocking of endogeneous peroxidase 
activity was done with 0.3% hydrogen peroxide in methanol, freshly 
prepared for twenty minutes. Then epitope retrieval was done by heating 
in microwave oven by using buffer of citrate at pH 6. 
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Immunohistochemistry was done by utilizing a monoclonal anti –
Cytokeratin 19 antibody (clone -RCK 108), a mouse monoclonal 
antibody obtained from ascitic  fluid  diluted with phosphate buffered 
saline containing 1% BSA and 0.09% sodium azide. This is a Ready-to-
Use antibody and does not require further dilution. 
IMMUNOHISTOCHEMISTRY: 
METHOD: 
Two – step indirect technique. 
PRINCIPLES OF THE PROCEDURE: 
Using a two stage process, antigens in cells and tissues were 
detected. 
The first was the binding to specific epitopes of the primary 
antibody. Second was a colorimetric reaction to detect the binding.  
Sections of tissues were fixed and attached to slides .The paraffin 
embedded sections were then dewaxed . Antigen retrieval procedure was 
done. This consisted of  heating the  formalin fixed sections  in 
microwave  oven in an aqueous solution. It recovered full antigenicity 
with most of the antibodies. These also included cases that were formerly 
unreactive with formalin – fixed tissue. Subsequently, the tissue sections 
were treated with Peroxide –Block and Power-Block for blocking 
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endogenous peroxidase and non specific protein-protein interactions, 
respectively. 
REAGENTS USED: 
1. Peroxide Block: 3% hydrogen peroxide in water. 
2.  Power Block Reagent:  A highly effective universal protein                                                                                                          
blocking   reagent. Contains casein and propriety additives in PBS 
with 15mM Sodium  azide. 
3. Chromogen:  DAB-3,3-diaminobenzidine. 
4. Liquid DAB Substrate: Comprises Tris- buffer containing  the 
peroxide and stabilizers. 
5. Super Enhancer Reagent 
6.  Poly-HRP Reagent 
7. Counter stain: Ehrlich’s hematoxylin 
BUFFER SOLUTIONS: 
TRIS BUFFER: (pH- 7.6) 
TRIS  Buffer salt: 0.605 gm 
Sodium chloride: 8gm 
Distilled water: 1000 ml 
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1 N Hydrochloric acid: 3 ml 
CITRATE BUFFER: (pH – 6.0) 
Trisodium citrate: 2.94 gm 
Distilled water: 1000 ml 
1 N  Hydrochloric acid: 5 ml 
          TRIS- EDTA: (pH – 9.0) 
TRIS Buffer salt: 6.05 gm 
Disodium  EDTA : 0.744 gm 
Distilled water : 1000 m 
 
PROCEDURE: 
1. Sections were deparaffinised in two changes of xylene, 15 minutes 
each. 
2. Sections are dehydrated in absolute alcohol for 5 minutes with 2 
changes. 
3. Sections are then washed in tap water for 10 minutes. 
4. Slides are then rinsed in distilled water for 5 minutes. 
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5. Antigen retrieval was done by placing them with appropriate buffer 
solution in microwave. Medium temperature – 10 minutes, high 
temperature – 10 minutes. 
6. They were then cooled to room temperature and rinsed in distilled 
water. 
7. Sections are then washed in TBS buffer for 5 minutes with 2 
changes. 
8. Then treated with Peroxide Block for 10 minutes. 
9. Again sections are washed in TBS buffer for 5 minutes with 2 
changes. 
10. Treated with Power Block for 10 minutes. 
11. Slides are then drained and covered with primary antibody (supplied 
from BioGenex) for 2 hours. 
12. Washed in TBS buffer for   5 minutes with 2 changes. 
13. Sections were covered with Super Enhancer for 30 minutes. 
14. Washed in TBS buffer for   5 minutes with 2 changes. 
15. Poly – HRP reagent was applied and left for 30 minutes. 
16. Washed in TBS buffer for   5 minutes with 2 changes. 
17. Treated with DAB Chromogen with Substrate buffer for 5 to 8 
minutes. 
18. Washed in TBS buffer for   5 minutes with 2 changes. 
19. They were then washed in tap water for 5 minutes. 
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20. Sections are counterstained with Ehrlich’s hematoxylin for 30 
seconds. 
21. Washed in tap water for 5 minutes. 
22. Slides were air dried and mounted with DPX. 
 Tumor cells were scored positive if there was golden brown 
cytoplasmic, nuclear or membrane staining in the neoplastic cells. 
Negative diagnosis was made when no golden brown staining was noted. 
Interpretation of immunohistochemistry : 
Cytokeratin 19: 
Positive staining refers to diffuse staining of cytoplasm. Intensity of 
positive staining is graded   between  0  to  3+  as below: 
S.No Grading Percentage of cells expressing CK19 positivity 
1. 0 (negative) No  positively staining cells 
2. 1+ (focally 
positive) 
<25% of positively staining cells 
3. 2+ (positive) 25 – 50% of positively staining cells 
4. 3+ (diffusely 
positive) 
>50% of positively staining cells 
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OBSERVATION AND RESULTS 
 The present study is a prospective study conducted in the 
Department of Pathology, Coimbatore Medical College Hospital. A total 
number of  30 cases of thyroidectomy specimens with different thyroid 
neoplasms, one with lymph node metastasis that were  received over the 
period of July 2014 to July 2015,  were taken for this study. 
Ethical clearance was obtained from Ethics committee of 
Coimbatore Medical College Hospital, Coimbatore. 
Histomorphological features and immunohistochemical expression 
pattern  of  Cytokeratin19 in thyroid nodules were  studied, analysed and 
compared with literature. 
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TABLE 1: AGE DISTRIBUTION IN THYROID 
NODULES: 
    Age in years 
 
No. of 
cases  
Percentage 
 
< 30 
 
8 
 
27% 
 
31 – 40 
 
8 
 
27% 
 
41 – 50 
 
12 
 
40% 
 
51 – 60 
 
2 
 
6% 
 
Total 
 
30 
 
100% 
 
 
In the present study the incidence of  thyroid nodules are common 
in the  age group between 41-50 years  comprising about 40%  (12 cases) 
of  the total cases followed by 31 to 40 years and less than 30 years each 
constituting 27% and 6% in the age group of  51- 60 years. 
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CHART 1: AGE DISTRIBUTION OF THYROID NODULES: 
 
 
The above bar diagram depicts the age incidence of thyroid 
nodules. Age group between 41- 50 years is commonly affected followed 
by 30- 40 years. 
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TABLE 2: SEX DISTRIBUTION OF THYROID NODULES: 
Gender No. of cases Percentage 
Male 3 10% 
Female 27 90% 
Total 30 100% 
 
 
CHART 2: SEX DISTRIBUTION OF THYROID NODULES: 
 
 As  per  the present study ,thyroid nodules are more common 
among  females constituting about 90% (27 cases) in contrast to males 
with only 3 cases comprising 10%. Female to male ratio is 3:1. 
  
MALE[n=3]
10%
FEMALE[n=27]
90%
GENDER DISTRIBUTION [N=30]
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TABLE 3: DISTRIBUTION OF DIFFERENT THYROID 
NEOPLASMS: 
 
 
In the present study of  comparison of  different thyroid neoplasms, 
follicular adenoma constitutes the majority of cases which is 50%, 
followed by papillary carcinoma- 37% (classic type-30%, follicular 
variant- 7%) and follicular carcinoma- 13%. 
 
 
 
 
 
Histopathological Diagnosis No. of cases Percentage 
Papillary Carcinoma 
Classic type 
Follicular variant 
11 
9 
2 
37% 
30% 
7% 
Follicular Carcinoma 4 13% 
Follicular Adenoma 15 50% 
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CHART 3: DISTRIBUTION OF VARIOUS THYROID 
NEOPLASMS: 
 
 
 
 
 
 
 
 
 From the above diagram, we observe that   follicular adenoma 
constitutes 50% followed by different thyroid carcinomas constituting 
totally 50%. 
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TABLE 4: ASSOCIATION OF AGE WITH 
HISTOPATHOLOGICAL DIAGNOSIS 
 
HPE DIAGNOSIS 
AGE (years) PC FC 
 
FA 
 
TOTAL 
< 30 5 0 
 
3 
 
8 
31 – 40 3 1 
 
4 
 
8 
41 – 50 3 1 
 
8 
 
12 
51- 60 0 2 
 
0 
 
2 
Total 11 4 
 
15 
 
30 
 
From the above table, it is observed that papillary carcinoma is 
commonly occurring between 30-50 years whereas follicular carcinoma is 
common in the age group between 51-60 years. 
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CHART 4: ASSOCIATION OF AGE WITH HPE DIAGNOSIS: 
 
In the present study papillary carcinoma is common in the age 
group less than 30 years constituting 47%, followed by the age group 
between 31-40 years and 41-50 years each comprising 27%, whereas 
follicular carcinoma is common in the age group between 51-60 years 
constituting 50%. Follicular adenoma occurs in   all age groups between 
30-60 years with predominance in 41-50 years comprising 53%. 
 
  
PC[n=11] FC[n=4] FA[n=15]
< 30 45% 0% 20%
31 - 40 27% 25% 27%
41 - 50 27% 25% 53%
51 - 60 0% 50% 0%
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Association of Age with HPE diagnosis [N=30][p<0.05]
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TABLE5: ASSOCIATION OF SEX WITH HPE DIAGNOSIS 
HPE DIAGNOSIS 
Gender PC FC FA TOTAL 
Male 1 1 1 3 
Female 10 3 14 27 
Total 11 4 15 30 
 
             From the above observations, in the present study, females have 
higher incidence of thyroid tumors than males.  Both benign (14 out of 15 
cases) and malignant tumors (13 out of 15 cases) are common in females. 
In males only 1 case of benign tumor occurred out of total 15 cases and 2 
malignant tumors out of total 15 cases. 
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CHART 5: ASSOCIATION OF SEX WITH 
HISTOPATHOLOGICAL DIAGNOSIS: 
 
In the present study both benign and malignant thyroid tumors are 
common in females than males.  The percentage  of  various neoplasms in 
females are as follows: 
Papillary carcinoma – 91% 
Follicular carcinoma- 75% 
Follicular adenoma- 93% 
 
 
 
 
PC[n=11] FC[n=4] FA[n=15]
Male 9% 25% 7%
Female 91% 75% 93%
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TABLE 6: VARIANTS OF DIFFERENT THYROID 
CARCINOMAS [N=30] 
 
 
             In the present study, classic variant of papillary carcinoma 
constituted majority of cases (9 cases out of 11 cases, one is 
encapsulated), and follicular variant of papillary carcinoma constituted 
only 2 cases. 
 
Variants of thyroid carcinoma 
HPE DIAGNOSIS 
PC FC TOTAL 
Classic Papillary Carcinoma 8 0 8 
 Encapsulated- Papillary Carcinoma 1 0 1 
 Follicular Variant – Papillary 
Carcinoma 2 0 2 
 Minimally Invasive  Follicular 
Carcinoma 0 1 1 
 Widely Invasive Follicular Carcinoma 0 3 3 
 Total 11 4 15 
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CHART 6: PROPORTION OF VARIANTS OF DIFFERENT 
THYROID CARCINOMAS: 
 
 
          In the present study the proportion of variants of different thyroid 
tumors are analysed and in papillary carcinoma classic type constitutes 
80% with follicular variant of papillary carcinoma comprising only 20%.        
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Encapsulated 
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TABLE 7: INCIDENCE OF PAPILLARY CARCINOMA 
VARIANTS: 
Papillary carcinoma variants No. of cases 
 
Percentage 
Classic 8 
 
73% 
Encapsulated (classic) 1 
 
9% 
Follicular variant 2 
 
18% 
Total 11 100% 
 
CHART 7: PERCENTAGE OF VARIANTS OF PAPILLARY 
CARCINOMA: 
 
The above diagram shows the percentage of papillary carcinoma 
variants that were received during our study period with classic type 73%, 
encapsulated variant-9% and follicular variant-18%. 
classic
73%
encapsulated
9%
follicular 
variant
18%
Papillary Carcinoma Variants 
[n=11]
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TABLE 8: INTENSITY OF STAINING OF CYTOKERATIN19 IN 
THYROID NODULES: 
 
HPE DIAGNOSIS 
   Staining of 
CK 19 PC FC FA PCFV TOTAL 
  0 0 3 13 0 16 
        1+ 0 1 2 1 4 
 
 2+ 1 0 0 1 2 
      3+ 8 0 0 0 8 
  Total 9 4 15 2 30 
   
(Note:  0: no cells are positive 
1+ :  <25% of cells are positive 
2+:  25%- 50% of cells are positive 
3+ :  > 50% of cells are positive 
PC : Papillary carcinoma 
PCFV: Papillary carcinoma  - Follicular variant 
FA : Follicular adenoma 
FC : Follicular Carcinoma) 
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CHART 8: INTENSITY OF STAINING OF CYTOKERATIN19 IN 
THYROID NODULES: 
 
 In the present study, staining intensity of  cytokeratin19 in classic 
papillary carcinoma shows  strong and diffuse positivity in 
cytoplasm of cells i.e. 3+ staining in 8 cases comprising 89% , with 
only 11% of cases showing moderate or 2 + staining. In follicular 
variant of papillary carcinoma 50% of cases showed 2 + positivity, 
50% of cases had 1 + positivity. 
 In follicular carcinoma cytokeratin19 is weakly positive i.e. 1+ in 
only 25%. 75% of the cases are negative for cytokeratin19 
 In follicular adenoma 1+ weak and focal positivity is obtained in 
13% of cases only. 87% of cases are negative for cytokeratin19. 
 Chi square test showed statistically significant p value of <0.001 
from the above variables. 
PC[n=9] FC[n=4] FA[n=15] PCFV[n=2]
0 0% 75% 87% 0%
1+ 0% 25% 13% 50%
2+ 11% 0% 0% 50%
3+ 89% 0% 0% 0%
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TABLE 9: INTENSITY OF STAINING OF CYTOKERATIN19 IN 
WELL DIFFERENTIATED THYROID CARCINOMA: 
STAINING INTENSITY OF CK19 0 1+ 2+ 3+ TOTAL 
NO. OF FC  CASES 3 1 0 0 4 
PERCENTAGE OF POSITIVITY IN 
FC 
75% 25% 0% 0% 100% 
NO. OF PC CASES 0 1 2 8 11 
PERCENTAGE OF POSITIVITY IN 
PC 
0% 9% 18% 73% 100% 
 
The above table shows that Cytokeratin19 positivity is strong and 
diffuse in papillary carcinoma, whereas focal and weak positivity in 
follicular carcinoma. 
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CHART 9: INTENSITY OF STAINING OF CK19 IN PAPILLARY 
CARCINOMA: 
 
In the present study, the varying intensity of  cytoplasmic staining 
of cytokeratin19 in papillary carcinoma including follicular variant of 
papillary carcinoma  showed  diffuse strong positivity of 3+  in 73% of 
cases , 2+  / moderate positivity in 18% of cases and weak positivity of 
1+ in only 9% of cases.   
None of the case of papillary carcinoma showed negative staining 
with cytokeratin19, thus implying its significant role in the diagnosis of 
papillary carcinoma and its variants. 
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TABLE 10: STATISTICAL ANALYSIS  DATAS  OF  
CYTOKERATIN 19  STAINING  IN THYROID NODULES: 
Thyroid tumors Sensitivity specificity 
Positive 
predictive 
value 
Negative 
predictive 
Value 
Classic papillary 
Carcinoma 
100% 84% 79% 100% 
Papillary 
carcinoma-
Follicular variant 
100% 57% 14% 100% 
Follicular 
carcinoma 
25% 50% 7% 81% 
Follicular 
adenoma 
13% 87% 50% 50% 
 
From the statistical analysis in this present study, it is found that 
cytokeratin19 is a sensitive and specific marker in the diagnosis of 
papillary carcinoma.  
 
(Note: Statistical analysis was done using SPSS software version and the 
variables are expressed as percentage (%). For statistical comparison 
Chi square test was used. p value of < 0.05 was considered as 
statistically significant.)  
  
 
 
 
 
 
 
 
 
REPRESENTATIVE PICTURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1. Papillary carcinoma of thyroid- H& E (10X) 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.2. Papillary carcinoma of thyroid showing nuclear grooves () and  
intranuclear  pseudoinclusion () – H & E (40X) 
 
 
 
 
     Fig.3. Diffuse 3+ cytoplasmic  positivity of cytokeratin19 in papillary  
        carcinoma (10 X)      
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4. 2+ positivity of Cytokeratin19 in papillary carcinoma (10X) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5. Follicular variant of papillary carcinoma – H & E (10X) 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.6 Follicular variant of papillary carcinoma showing 2+ positivity with 
cytokeratin19 (10X) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.7 Follicular variant of papillary carcinoma showing 1+ positivity with 
cytokeratin19 (10X) 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                       Fig.8. Follicular carcinoma of thyroid with capsular invasion- H & E (10X) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.9. Follicular carcinoma of thyroid showing vascular invasion- H & E (10X) 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.10. Follicular carcinoma of thyroid showing focal 1+ positivity with 
cytokeratin19 (10X) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.11. Follicular carcinoma showing negative staining with cytokeratin19 (10X) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.12. Follicular adenoma – H & E (10X) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.13. Follicular adenoma showing focal 1+ positivity with cytokeratin19 (10X) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.14. Follicular adenoma showing negative staining with cytokeratin19 (10X) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.15. Metastatic papillary carcinoma deposits in lymph node – H & E (10X) 
 
 
 
 
 
 
 
 
  
 
 
 
Fig.16. Diffuse 3+ positivity of cytokeratin19 in metastatic papillary carcinoma 
deposits foci in lymph node 
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DISCUSSION 
Diagnosis of thyroid lesions by the routine hematoxylin and eosin 
stained sections is really challenging because of the overlapping 
histological features in various thyroid lesions. Interpretation of thyroid 
lesions with follicular pattern is quite difficult. Also in papillary 
carcinoma not all the characteristic nuclear features are present in same 
case. 
Additionally, encapsulated tumors with follicular pattern pose 
dilemma in differentiating benign from malignant thyroid neoplasm, 
when the neoplastic nodule has incomplete capsular invasion or equivocal 
vascular invasion. Tumors having some nuclear features of papillary 
carcinoma but not having papillary structures i.e. follicular variant of 
papillary carcinoma is difficult to distinguish from other follicular 
patterned lesions. This issue is clearly pointed out by Elsheikh et al, in 
their recent study and was reviewed and confirmed by J.Rosai  in  2008.82 
Thyroid  nodules are common worldwide and affects 40% of the 
population. They are common in females and in age group between 30- 
60 years. 
But 80% of the thyroid nodules are benign neoplasm or 
hyperplastic nodules. 
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Thyroid malignancies are the most common endocrine carcinomas 
comprising 5- 10%. Each year 3.6% of new cases of thyroid cancer occur. 
To aid in better clinical management and to obtain maximum benefit it is 
very essential to identify  the  benign lesions. Incorrect diagnosis may 
lead to stress, both psychologically and socially in patients and they may 
incur unwanted healthcare expenditure. No definite diagnostic modalities 
are available to differentiate the thyroid lesions. Fine needle aspiration 
cytology is still routinely used as screening test for thyroid lesions, but it 
is not reliable in differentiating benign and malignant tumors. 
In view of all these shortcomings, nowadays a panel of 
immunohistochemical markers are used that help in the distinction  of  
benign and malignant thyroid lesions. In this present study, the usefulness 
of cytokeratin19 in differential diagnosis  of  various thyroid nodules  is 
analysed and its occurrence is correlated with age and sex of the patients  
and  also with histomorphology. 
The observation and results of previously conducted studies that 
are relevant to this present study are as follows: 
As per the study conducted conducted by Al-Zaher N et al in 2008,  
thyroid nodules  most commonly occured in the  age group  between 25 
to 65 years.83 
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In the present study, we have also observed the similar results, and 
thyroid nodules are  common  between 30- 50 years with 24 cases out of 
30, followed by  age group of 51 – 60 years as shown in table 1. 
         American cancer society in their statistical analysis of thyroid 
lesions in the year 2010,  reported  that  thyroid nodules both benign and 
malignant, are  2 to 3  times, more common in females than males.84 
           In the present study, we  also  observed  that female to male ratio 
of incidence of thyroid nodules is 3:1as shown in table2 & 5. Thus it 
correlates with previous study. 
           National Cancer Institute in 2013,  analysed the proportion of  
various thyroid carcinoma and found that  papillary thyroid carcinoma is 
the predominant malignancy constituting 70- 80%  of all thyroid cancers. 
They are common in females between 30- 50 years as per their study. The 
next common malignancy is Follicular carcinoma constituting 10- 15% 
of all thyroid malignancies and is common in females in the age group of 
40-60 years.10 
          In this present  study, we have also obtained similar results with 
papillary carcinoma constituting 73%, followed by follicular carcinoma 
26%. Both papillary and follicular carcinomas are common in females 
constituting 91% and 75% respectively. Papillary carcinoma is common 
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in the age group between 30- 50 years (all 11 cases), and follicular 
carcinoma between 40- 60 years  in our study (3 cases out of 4) as shown 
in table4 & 5. Chi square test was done and these results were found to be 
statistically significant with p value < 0.05 
              Fabio Muradas Girardi et al, in 2013 studied the prevalence of 
thyroid carcinoma variants in a single centre .85 They have found that 
 Classic variant of papillary carcinoma- 31.7% 
 Follicular variant – 16% 
 Oncocytic variant- 1.9% 
 Other variants- 0.1- 0.7%. 
In our present study  we received 11 papillary thyroid carcinoma of 
which 9 are classic type including one encapsulated  variant comprising  
82% followed by follicular variant – 18% as shown in table. We have not 
received other variants in our study period. Thus it correlates with the 
previous study of predominance of classic variant. 
Hanan Alsaeid Alshenawy  studied the usefulness of cytokeratin19 
in thyroid nodules during the year 2009-2013 and observed cytokeratin19  
positivity in 57% of  follicular adenoma i.e. 4 cases out of total 7 cases (1 
case focally positive 1+, 3 cases showed 2+ positivity).15 
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Husain A Saleh et al in 2008, in their study reported cytokeratin19 
positivity in 30% (23 cases out of 46 total cases) of cases of follicular 
adenoma and the intensity of staining is weak and focal.86 
In our present study,  we have also obtained  the similar results of 
weak and focal positivity with cytokeratin19 i.e. 1+ ( < 25%  of cells) in 
only 2 cases out of total 15 cases, constituting 13% as shown in table and 
chart 8. Hence cytokeratin19 is not a sensitive marker in the diagnosis of 
follicular adenoma. But it has higher specificity of 87% in differentiation 
of benign from malignant tumors. 
The sensitivity and specificity of  cytokeratin19 in follicular 
adenoma in this study is 13% and 87% respectively. 
Hanan Alsaeid Alshenawy , in his study found out that 
cytokeratin19 showed positivity in 53% of  cases of follicular carcinoma, 
i.e. 8cases out of total 15 cases (2 cases with positivity in < 25% of cells  
- 1+, 2 cases with 2+  positivity  about  25-50% of cells and  and 4 cases 
with  >50% of cells , 3+ positivity) .15 
K.Y Lam et al in 2001, reported focal positivity in 68% of 
follicular carcinoma, 13 cases out of total 19 cases with cytokeratin19.87 
In this present study we obtained focal and weak  1+ positivity in 
only 1 case out of total 4 cases of follicular carcinoma constituting 25%. 
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All other 3 cases are negative as shown in table and chart 8. Thus it 
correlates with previous studies. 
The sensitivity and specificity of  cytokeratin19  in follicular 
carcinoma in this study is 25%  and 50% respectively.  . 
 Hanan Alsaeid Alshenawy, in his study found out that 
cytokeratin19 is always positive in papillary carcinoma incontrast  to 
other thyroid malignancies.15 He reported that all 14 cases of papillary 
carcinoma showed positivity with cytokeratin 19 comprising 100%. 13 
cases showed strong and diffuse positivity of 3+ and only one case 
showed 2+  intensity. In follicular variant of papillary carcinoma all 8 
cases showed positive staining with 5 cases showing 2+ intensity and 
remaining 3 cases with 3+ positivity. 
He also found that cytokeratin19 has 100% sensitivity and 77% 
specificity in differentiating papillary thyroid carcinoma from other 
follicular neoplasm. 
Husain A Saleh  et al reported 85% positivity of  classic papillary 
carcinoma cases with cytokeratin19, (17 cases out of 20)  and 83.3% in 
follicular variant of papillary carcinoma ( 10 out of 12 cases).86 
Lei Gong et al in 2012, reported 100% strong and diffuse  
positivity with cytokeratin19 in papillary carcinoma.88 
87  
Carol C Chereng et al  in 2001, observed strong and diffuse 
positivity with cytokeratin19 in 80% of  classic papillary carcinoma and 
in 57% of follicular variant of papillary carcinoma and concluded that it 
is a sensitive marker.89 
Sahoos et al studied the utility of cytokeratin19 in the diagnosis of 
papillary  carcinoma  and  reported in 2001 that cytokeratin19 is sensitive 
marker showing 100% positivity in papillary carcinoma including the 
follicular variant. 90They got diffuse 3+ positivity in all 5 classic papillary 
carcinoma and 3+ in 9 cases out of 10, in follicular variant of papillary 
carcinoma. Only one case out of 10 showed moderate / 2+ positivity. 
Dina El Demellawy et al reported in 2008, cytokeratin19 positivity 
in 85% of cases of papillary carcinoma which included both classic and 
follicular variant.91 
In this present study, the results obtained are so alike with all the 
aforementioned studies. We studied the cytokeratin19 staining in total of 
11 cases of papillary carcinoma including follicular variant. All the 11 
cases showed positive staining (100%) with cytokeratin19 but with 
varying intensity. In classic papillary carcinoma out of 9 cases only one 
case (11%) showed 2+ intensity of staining. All other 8 cases had diffuse 
and strong positivity of 3+ (89%).   
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1 out of the total 9 cases of classic papillary carcinoma had cervical 
lymph node metastasis and cytokertin19 showed diffuse and strong 3+ 
positivity in the foci of  papillary carcinoma deposits  in the node.  
In the total of  2 cases of follicular variant of papillary  one showed 
1+ intensity and other  showed 2+ intensity of staining as in table 8. 
The sensitivity and specificity of cytokeratin19 in papillary 
carcinoma is 100% and 84% respectively. Chi square test of these 
variables showed statistically significant p value of < 0.001. 
The results of this present study are in conformity with the 
previously conducted studies and thus immunomarker cytokeratin19 
plays a pivot role in differentiation of thyroid nodules. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
SUMMARY AND CONCLUSION 
89  
SUMMARY AND CONCLUSION 
             Thyroid lesions are common worldwide with a prevalence of 40 
million per year. 80% of the thyroid nodules are benign. As the treatment 
modalities are improving in recent years, correct diagnosis aids in better 
patient outcome and survival rate. Immunohistochemistry helps in 
arriving at exact diagnosis in controversial cases.  Cytokeratin19, an 
intermediate filament protein in epithelial cells shows variable staining in 
different thyroid lesions and thus helps in differentiating thyroid tumors 
especially, papillary carcinoma and its variants. 
In the present study we included 30 cases of different thyroid 
lesions which included follicular adenoma (15 cases), follicular 
carcinoma (4cases) and papillary carcinoma with its follicular variant (11 
cases), one case with lymph node metastasis  and  obtained the following 
results. 
The incidence of  thyroid  nodules  are common between the age 
group 30-60 years and females are commonly affected than males. 
Female to male ratio is 3:1. 
In the present study we observed that papillary carcinoma is more 
common comprising 73% followed by follicular carcinoma (26%). These 
values are studied by chi square test and obtained statistically significant 
p value of < 0.05. 
90  
Both benign and malignant thyroid neoplasm are common in 
females with an incidence of 90% in contrary to only 10% in males.  In 
females, papillary carcinoma is most common in age group between 30 – 
50 years, whereas  follicular carcinoma  occurred in age group between 
40-60 years (75%) . 
CYTOKERATIN19 EXPRESSION IN VARIOUS THYROID 
NEOPLASM ARE OBSERVED AS FOLLOWS: 
In classic papillary carcinoma cytokeratin19 showed  diffuse  and 
strong  3+  (>50% of cells) cytoplasmic  positivity in 89% of cases. Only 
one case showed 2+ (25%-50%)  positivity constituting 11%.  
In one of the classic papillary carcinoma with lymph node 
metastasis, metastatic foci of papillary carcinoma also showed diffuse and 
strong 3+  positivity with cytokeratin19.         
In follicular variant of papillary carcinoma one case showed focal 
1+  positivity with cytokeratin19 and the other case showed 2+ positivity. 
The sensitivity of cytokeratin19 in papillary carcinoma is 100% and 
specificity is 84%.  
The positive predictive value is 79%. Chi square analysis of these 
variables showed statistically significant p value of < 0.001. 
In follicular carcinoma, 75% of the cases showed negativity with 
cytokeratin19 and 25% of cases showed weak  and focal 1+ intensity of 
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staining (< 25% of cells). The sensitivity and specificity is 25% and 50% 
respectively. 
In follicular adenoma, cytokeratin19 showed negativity in 87% of 
cases with only 13% of cases showing weak and focal 1+  positivity. The 
sensitivity is 13% and specificity 87%. 
              Our findings in the present study indicate that, cytokeratin19 
showed varying intensity of staining in different thyroid lesions. 
Cytokeratin19 showed 100% positivity in papillary carcinoma and is 
found to be a sensitive and specific marker in the diagnosis of papillary 
carcinoma and its variants. Cytokeratin19 is also useful in diagnosing 
papillary carcinoma with tubulopapillary pattern provided the staining is 
strong and diffuse.  Cytokeratin19  in  conjunction  with  TTF1 and 
PAX8 can also be used to confirm the diagnosis of  metastatic deposits of 
papillary carcinoma of  thyroid with occult primary. 
               Cytokeratin19 does not differentiate follicular adenoma from 
follicular carcinoma. Though the present study showed more sensitivity 
in differentiating follicular variant of papillary carcinoma from follicular 
carcinoma, a definite conclusion cannot be made in this regard, as 
minimum  number  of  cases of  follicular carcinoma and follicular 
variant of papillary carcinoma have been studied.     
        In such instances, a panel of markers like Galectin3, HBME1 and 
CD56 may aid in exact differentiation of  these neoplasms and it needs a 
further detailed research in future. 
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ANNEXURE I 
 
 
ANNEXURE 1 
PROFORMA 
Coimbatore medical college 
Department of   Pathology 
Coimbatore 
Particulars of the patient: 
Name  :                                                          Age: 
Ward    :                                                       IP. No : 
Address:                                                       Occupation: 
 Presenting complaints: 
Swelling  infront of   the  neck                             Pain  
Onset and progression                                           Difficulty in swallowing 
Change of voice                                                    Bowel habits 
Menstrual disturbances in female                         Hypo/ hyperthyroidism            
             symptoms 
 Loss of  appetite and weight                                                                                         
Other swellings in neck and other regions. 
 
 
Past history: 
History of radiation exposure to head and neck 
History of previous surgeries 
Family history 
Personal history: 
Diet 
General examination:              
Nourishment :                    Built:                                              Conscious:        
Pallor:                                 Jaundice:                                         Clubbing: 
Febrile/afebrile                    Lymphadenopathy :                        Edema: 
Tremors:                             eye signs: 
Vitals: 
Pulse rate:                     BP:                RR:        
Local examination:             
Site :                                    Size:                            Shape: 
Solitary nodule / multinodular 
Whether Moving with deglutition or not  
 
 
Fixity to surrounding structures 
Lymphadenopathy: cervical and other region 
Clinical diagnosis: 
Investigations: 
Thyroid hormone profile  
USG report 
Fine needle aspiration cytology report 
Microscopic findings: 
Histopathological diagnosis 
Immunohistochemistry: 
FINAL DIAGNOSIS 
 
 
 
 
 
 
  
CONSENT FORM 
      Dr. P. Suriyaprabha, postgraduate student in the department of 
pathology, Coimbatore  Medical College is conducting a study on 
“IMMUNOHISTOCHEMICAL EXPRESSION OF CK-19 IN 
THYROID NODULES AND ITS CORRELATION WITH 
HISTOPATHOLOGY”. Thyroidectomy done for various thyroid lesions  
are received in pathology department and  are processed and examined 
under a microscope to obtain diagnostic information or is tested for other 
studies.  I  have been informed, to my satisfaction regarding the nature of 
surgical procedure. The data used herein may be used for research and 
publication.  
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 muR nfhit kUj;Jtf; fy;Y}hpapy; neha; Fwpapay; kUj;jt 
Jiwapy; gl;;l nkw;gog;g[ gapYk; khztp kU.g.Nh;agpugh mth;fs; 
nkw;bfhs;Sk; “ijuha;L fl;oapy; irl;nlhbfuhod; 19dpd; btspg;ghl;oid 
mwpjy;” gw;wpa Ma;tpy; bra;Kiw kw;Wk; midj;J tpsf;f';fisa[k; 
nfl;Lf; bfhz;L vdJ re;njf';fis bjspt[g;gLj;jpf; bfhz;nld; vd;gij 
bjhptpj;Jf; bfhs;fpnwd;. 
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,e;j Ma;tpy; ,Ue;J ehd; tpyfpf; bfhs;s vdf;F chpik cz;L 
vd;gija[k; mwpntd;. 
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ANNEXURE II 
 
 
ANNEXUREII  -  MASTER CHART 
SERIAL 
NO. IP.NO AGE SEX HPE.NO. HPE DIAGNOSIS VARIANT CK19 POSITIVITY 
INTENSITY OF CK19 
STAINING 
1 73070 28 f 3773/14 PC classic diffuse positivity 3+ 
2 565687 19  f p522/14 PC encapsulated  diffuse positivity 3+ 
3 49540 50  f 2737/14 PC classic diffuse positivity 3+ 
4 55804 45 f 3074/14 PC classic diffuse positivity 3+ 
5 81793 32  f  01/15 PC classic diffuse positivity 3+ 
6 80948 40 f 149/15 PC with LN mets. classic positive 2+ 
7 45561 50 f 2601/14 PC classic diffuse positivity 3+ 
8 81924 40 f 297/15 PC classic diffuse positivity 3+ 
9 37888 30 f 1925/15 PC classic diffuse positivity 3+ 
10 80254 27 m 4349/14 PC follicular variant focally positive 1+ 
11 49870 29 f 2528/15 PC follicular variant focally positive 2+ 
12 9499 56 m 638/15 FC widely invasive negative 0 
13 73517 55 f 4235/14 FC 
minimally 
invasive negative 0 
14 32391 39 f 1620/15 FC widely invasive focally positive 1+ 
15 41535 45 f 2325/15 FC widely invasive negative 0 
16 35851 35 f 2161/14 FA   focally positive 1+ 
17 36271 48 f 2169/14 FA   negative 0 
18 52681 23 f 3002/14 FA   negative 0 
19 54740 28 f 3003/14 FA   focally positive 1+ 
20 7006 35 f 556/14 FA   negative 0 
21 43993 45 f 2544/14 FA   negative 0 
 
 
22 17294 42 f 1026/14 FA   Negative 0 
23 48298 50 f 2777/14 FA   Negative 0 
24 53123 50 f 2933/14 FA   Negative 0 
25 57595 50 f 3187/14 FA   Negative 0 
26 58456 35 f 3747/14 FA   Negative 0 
27 28474 32 m 1599/14 FA   Negative 0 
28 29424 42 f 1699/14 FA   Negative 0 
29 29121 18 f 1716/15 FA   Negative 0 
30 33513 44 f 1680/15 FA   Negative 0 
 
KEY WORDS 
PC- papillary carcinoma  
LN  mets - lymph node metastasis 
 FC- follicular carcinoma 
FA- follicular adenoma 
CK19- cytokeratin19
  
 
 
 
 
 
 
 
 
 
 
 
ANNEXURE III 
 
 
ANNEXURE III- LIST OF ABBREVIATIONS 
CK19                  -       Cytokeratin 19 
HBME-1             -       Hector Battifora Mesothelial-1 
TTF-1                 -       Thyroid transcription factor -1 
EMA                  -        Epithelial membrane anigen 
CEA                   -       Carcinoembryonic antigen 
NSE                   -       Neuron specific enolase 
PC                       -       Papillary carcinoma  
PCFV                  -       Papillary carcinoma – follicular variant 
FC                       -       Follicular carcinoma 
FA                       -       Follicular adenoma 
H&E                    -       Hematoxylin and eosin 
IHC                      -      Immunohistochemistry 
 
                                     
  
